The Plasminogen Activation System in Human Colon Cancer: Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor Stroma

Cancer Research

Volumn 51, Issue 15, 1991, Pages 4067-4071

  Walker, Cheryl ^b   Kristensen, P ^a   Ralfkiaer, E ^a   Eriksen, J ^a   Dano K ^a  

^a FINSEN LABORATORY   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR;

ANGIOGENESIS; ARTICLE; CANCER CELL; CARCINOGENESIS; COLON ADENOCARCINOMA; DNA TEMPLATE; ENDOTHELIUM CELL; GRANULATION TISSUE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; PLASMID; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; TUMOR CELL;

ADENOCARCINOMA; ANTISENSE ELEMENTS (GENETICS); COLONIC NEOPLASMS; DNA; ENDOTHELIUM, VASCULAR; HUMAN; NUCLEIC ACID HYBRIDIZATION; PLASMINOGEN INACTIVATORS; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T;

EID: 0026377425     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Dane, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
2. Blasi, F., Vassalli,. IO., and Dann. K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol., 104: 801-804, 1987.
3. Saksela, O., and Rifkin, D. B. Cell-associated plasminogen activation: regu lation and physiological functions. Annu. Rev. Cell Biol., 4: 93-126, 1988.
4. Pollanan, J., Stephens, R. W., and Vaheri, A. Directed plasminogen activa tion at the surface of normal and malignant cells. Adv. Cancer Res., in press, 1991.
5. Tryggvason, K., Hoyhtya, M., and Salo, T. Proteolytic degradation of extra cellular matrix in tumor invasion. Biochim. Biophys. Acta, 907: 191-217, 1987.
6. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
7. Jin, L., Nakajima, M., and Nicolson, G. L. Immunochemical localization of heparanase in mouse and human melanomas. Int. J. Cancer, 45:1088-1095, 1990.
8. Rochefort, H., Augereau, P., Briozzo, P., Capony, F., Cavailles, V., Freiss, G., Garcia, M., Maudelonde, T., Morisset, M., Touitou, I., and Vignon, F. Oestrogen-induced procathepsin D in breast cancer: from biology to clinical applications. Proc. R. Soc. Edinb. Sect. B (Biol.), 95: 107-118, 1989.
9. Skriver, L., Nielsen, L. S., Stephens, R., and Dane, K. Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur. J. Biochem., 124:409-414, 1982.
10. Ellis, V., Scully, M. F., and Kakkar, V. V. Plasminoceli activation by singlechain urokinase in functional isolation. J. Biol. Chem., 262: 14998-15003, 1987.
11. Petersen, L. C., Lund, L. R., Nielsen, L. S., Dano, K., and Skriver, L. Onechain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem., 263: 11189-11195,1988.
12. Vassalli, J-D., Baccino, I., and Belin, D. A cellular binding site for the M, 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol., 100: 86-92, 1985.
13. Stoppelli, M. P., Corti, A., Sofffientini, A., Cassani, G., Blasi, F., and Associan, R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Nati. Acad. Sci. USA, 82: 4939-4943, 1985.
14. Behrendt, N., Konno, E., Ploug, M., Petri,T., Lober, D., Nielsen, L. S., Schleuning, W-D., Blasi, F., Appella, E., and Dann. K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem., 265: 6453-6460, 1990.
15. Roldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Dano, K., Appella, E., and Blasi, F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J., 9: 467-474, 1990.
16. Ellis, V., Scully, M. F., and Kakkar, V. V. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem., 264: 2185-2188, 1989.
17. Stephens, R. W., Pallanen, J., Tapiovaara, H., Leung, K.-C., Sim, P.-S., Salonen, E.-M., Kanne, E., Behrendt, N., Dann, K., and Vaheri, A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol., 108: 1987-1995, 1989.
18. Andreasen, P. A., Nielsen, L. S., Kristensen, P., Grondahl-Hansen, J., Skriver, L., and Dann, K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem., 261: 7644-7651, 1986.
19. Cubellis, M. V., Wun, T. C., and Blasi, F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J., 9:1079-1085, 1990.
20. Ellis, V., Wun, T. C., Behrendt, N., R0nne, E., and Dane, K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem., 265: 9904-9908, 1990.
21. Seifen, S. C., and Gelehrter, T. D. Isolation of rat hepatoma cell variants selectively resistant to dexamethasone inhibition of plasminogen activator. J. Cell. Physiol., 99: 333-342, 1979.
22. Schleef, R. R., and Loskutoff, D. J. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis, IH: 328-341, 1988.
23. Andreasen, P. A., Georg, B., Lund, L. R., Riccio, A., and Stacey, S. N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrino!., 68: 1-19, 1990.
24. Dane, K., Andreasen, P. A., Behrendt, N., Grnndahl-Hansen, J., Kristensen, P., and Lund, L. R. Regulation of the urokinase pathway of plasminogen activation. Dev. Funct. Reprod. Organs, 2: 259-278, 1988.
25. Lund, L. R., Rumie. E., Roldan, A. L., Behrendt, N., Remer, J., Blasi, F., and Dann. K. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J. Biol. Chem., 266: 5177-5181, 1991.
26. Astedt, B., Haegerstrand, I., and Lecander, I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb. Haemostasis, 56: 63-65, 1986.
27. Feinberg, R. F., Kao, L.-C., Haimowitz, J. E., Queenan, J. T., Wun, T.-C., Strauss, J. F., and Kliman, H. J. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. Lab. Invest., 61: 20-26, 1989.
28. Eriksen, J., Kristensen, P., Pyke, C., and Dann, K. Plasminogen activator inhibitor (type-1) in rat adrenal medulla. Histochemistry, 92:377-383,1990.
29. Kristensen, P., Pyke, C., Lund, L. R., Andreasen, P. A., and Dane, K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochem istry, 93: 559-566, 1990.
30. Corasanti, J. G., Celik, C., Camiolo, S. M., Mittelman, A., Evers, J. I., Barbaseli. A., Hobika, G. H., and Markus, G. Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification. J. Nati. Cancer Inst., 65: 345-351, 1980.
31. de Bruin, P. A. F., Griffioen, G., Verspaget, H. W., Verheijen, J. H., Dooijewaard, G., van den Ingh, H. F., and Lamers, C. B. H. W. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res., 48: 4520-4524, 1988.
32. Gelister, J. S. K., Lewin, M. R., Driver, H. E., Savage, F., Mahmoud, M., Gaffney, P. J., and Boulos, P. B. Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence? Gut, 28: 816-821, 1987.
33. Nishino, N., Aoki, K., Tokura, Y., Sakaguchi, S., Takada, Y., and Takada, A. The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb. Res., 50: 527-535, 1988.
34. Sim, P.-S., Stephens, R. W., Fayle, D. R. H., and Doe, W. F. Urokinasetype plasminogen activator in colorectal carcinomas and adenomatous pol yps: a quantitative expression of active and proenzyme. Int. J. Cancer, 42: 483-488, 1988.
35. Tissot, J.-D., Hauert, J., and Bachmann, F. Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int. J. Cancer, 34: 295-302, 1984.
36. Grnndahl-Hansen, J., Ralfkiaer, E., Kirkeby, L. T., Kristensen, P., Lund, L. R., and Dano, K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinoma of the colon in man. Am. J. Pathol., 138: 111-117, 1991.
37. Pyke, C., Kristensen, P., Ralfkiaer, E., Grøndahl Hansen. J., Eriksen, J., Blasi, F., and Dane, K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol., 138: 1059-1067, 1991.
38. Andreasen, P. A., Riccio, A., Welinder, K. G., Douglas, R., Sartorio, R., Nielsen, L. S., Oppenheimer, C., Blasi, F., and Danø,K. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett., 209: 213-218, 1986.
39. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
40. Kristensen, P., Eriksen, J., and Dano, K. Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J. Histochem. Cytochem., 39: 341-349, 1991.
41. Sternberger, L. A., Hardy, P. H., Cuculis, J. J., and Meyer, H. G. The unlabelled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidaseantiperoxidase) and its use in identification of spirochaetes. J. Histochem. Cytochem., 18: 315, 1970.
42. Kristensen, P., Larsson, L-I., Nielsen, L. S., Grnndahl-Hansen, J., Andreasen, P. A., and Dann, K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett., 168: 33-37, 1984.
43. Boyd, D., Florent, G., Kim, P., and Brattain, M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res., 48: 3112-3116, 1988.
44. Plow, E. F., Freaney, D. E., Plescia, J., and Miles, L. A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol., 103: 2411-2420, 1986.
45. Declerck, P. J., De Mol, M., Alessi, M.C., Baudner, S., Paques, E-P., Preissner, K. T., Muller-Berghaus, G., and Collen, D. Purification and characterization of a plasminogen activator inhibitor I binding protein from human plasma. Identification as a multimene form of S protein (vitronectin). J. Biol. Chem., 263: 15454-15461, 1988.
46. Mimuro, J., and Loskutoff, D. J. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J. Biol. Chem., 264: 5058-5063, 1989.
47. Salonen, E-M., Vaheri, A., Pallane, J., Stephens, R., Andreasen, P., Mayer, M., Dann. K., Gailit, J., and Ruoslathi, E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J. Biol. Chem., 264:6339-6343, 1989.
48. Wun, T-C, Palmier, M. O., Siegel, N. R., and Smith, C. E. Affinity purifi cation of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. J. Biol. Chem., 264: 7862-7868, 1989.
49. Preissner, K. T. Specific binding of plasminogen to vitronectinaevidence for a umilii hum >role of vitronectin on fibrin(ogen)-induced plasmin forma tion by tissue plasminogen activator. Biochem. Biophys. Res. Commun., 168: 966-971, 1990.
50. Mimuro, J., Schleef, R. R., and Loskutoff, D. J. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood, 70: 721-728, 1987.
51. Levin, E. G., and Santell, L. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J. Cell. Biol., 105: 2543-2549, 1987.
52. Barnathan, E. S., Kuo, A., Van der Keyl, H., McCrae, K. R., Larsen, G. R., and Cines, D. B. Tissue-type plasminogen activator binding to human endo thelial cells. Evidence for two distinct binding sites. J. Biol. Chem., 263: 7792-7799,1988.
53. Hajjar, K. A., and Hamel, N. M. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J. Biol. Chem., 265: 2908-2916, 1990.
54. Morton, P. A., Owensby, D. A., Wun, T.-C., Billadello, J. J., and Schwartz, A. L. Identification of determinants involved in binding of tissue-type plas minogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells. J. Biol. Chem., 265: 14093-14099, 1990.
55. Ohtani, H., and Sasano, N. Microvascular changes in the stroma of human colorectal carcinomas: ultrastructural histochemical study. Jpn. J. Cancer Res., 80:360-365, 1989.
56. Moscatelli, D., and Rillin. D. B. Membrane and matrix localization of proteases: a common theme in tumor cell invasion and angiogenesis. Biochim. Biophys. Acta, 948:67-85, 1988.
57. Montesano, R., Pepper, M. S., Mohlesteinlein, U., Risau, W., Wagner, E. F., and Orci, L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T-oncogene. Cell, 62: 435-445, 1990.